Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Status:
Completed
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients
with cervical cancer that has come back, remains despite treatment, or has spread to other
places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may shrink
tumor cell and interfere with the ability of tumor cells to grow and spread.